AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 201 min read$MYGN

Myriad Genetics, Inc. (MYGN) To Sell Prenatal Health Unit To Labcorp For $210M Cash

Myriad Genetics (MYGN) will sell its Prenatal Health unit to Labcorp for $210M in cash, plus inventory value. The deal is subject to regulatory approval and expected to close by early 2027. Myriad aims to focus on cancer diagnostics, while Labcorp expands its testing services.

Original reporting
tradingview.com
Published Oct 20, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Myriad Genetics, Inc. (MYGN) To Sell Prenatal Health Unit To Labcorp For $210M Cash — source image
Source · tradingview.com
Decision brief

The 30-second read

$MYGNBearishHigh
01

Why it matters

The transaction provides immediate cash to Myriad while expanding Labcorp's test menu, potentially reshaping competitive dynamics.

02

Market read

First report of a $210M divestiture that could move both stocks.

03

What to watch

Regulatory clearance risk and integration costs for Labcorp may temper upside.

Relevance 8/10Novelty 9/10Timing: immediate

Background

Myriad Genetics is refocusing on cancer diagnostics; Labcorp seeks to broaden its specialty testing suite.

Company-level read

Ticker impact

$MYGNBearishHigh confidence
Context

Myriad Genetics announced it will sell its Prenatal Health unit to Labcorp for $210M cash.

Expected impact

likely downward pressure as investors price in loss of revenue from the unit

Evidence & confidence

The cash deal removes a business segment; market typically reacts negatively to asset sales without clear accretion guidance.

$LHBullishHigh confidence
Context

Labcorp agreed to acquire Myriad's Prenatal Health testing business for $210M cash.

Expected impact

potential upside as the market values the added testing capabilities

Evidence & confidence

Strategic fit and cash purchase may be seen as accretive, supporting a modest price lift.

Market effects

Sector

Strengthens the specialty diagnostics sector, may boost peers.

Regional

U.S. healthcare market sees consolidation activity.

Global

Limited to U.S. biotech and diagnostics investors.

Counterpoint

What could challenge this read

The sale could signal Myriad's focus shift away from growth areas, hurting long-term prospects.

Key entities

  • company
    Myriad Genetics, Inc.

    Seller of the Prenatal Health unit.

  • company
    Labcorp

    Buyer acquiring the Prenatal Health unit.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

6 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min
OCT 20
$MYGNHighAI 8/10

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

gurufocus.com2 min